National investment case development for pathogen genomics

Abstract

Sustaining and expanding genomic surveillance capacity requires broader investment in genomics that target both novel and pandemic pathogens. Currently, there is no standardized methodology to evaluate the cost and benefit of a multi-pathogen surveillance system. We propose a framework for pathogen genomic surveillance that links public health and systems considerations to a stepwise approach.

Keywords: disease surveillance; genomics; global health; investment case; next-generation sequencing; pandemic preparedness; pathogen genomics; surveillance.